Company Description
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally.
It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy.
In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation.
Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure.
The company distributes its products through a direct sales force and independent distributors.
Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Country | United States |
IPO Date | Mar 27, 2000 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 19,800 |
CEO | Bernard J. Zovighian |
Contact Details
Address: One Edwards Way Irvine, California United States | |
Website | https://www.edwards.com |
Stock Details
Ticker Symbol | EW |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001099800 |
CUSIP Number | 28176E108 |
ISIN Number | US28176E1082 |
Employer ID | 36-4316614 |
SIC Code | 3842 |
Key Executives
Name | Position |
---|---|
Bernard J. Zovighian | Chief Executive Officer & Director |
Scott B. Ullem | Corporate Vice President & Chief Financial Officer |
Andrew M. Dahl | Principal Accounting Officer, Senior Vice President & Corporate Controller |
Arnold A. Pinkston J.D. | Corporate Vice President & General Counsel |
Christine Z. McCauley | Corporate Vice President of Human Resources |
Dirksen J. Lehman | Corporate Vice President of Public Affairs |
Donald E. Bobo Jr. | Corporate Vice President of Strategy & Corporate Development |
Dr. Todd J. Brinton FACC, M.D. | Corporate Vice President of Advanced Technology & Chief Scientific Officer |
Larry L. Wood | Corporate Vice President and Group President of TAVR & Surgical Structural Heart |
Mark Wilterding | Vice President of Investor Relations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 09, 2024 | 4 | Filing |
Dec 09, 2024 | 4 | Filing |
Dec 06, 2024 | 4 | Filing |
Dec 06, 2024 | 4 | Filing |
Nov 13, 2024 | 4 | Filing |
Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 06, 2024 | 10-Q | Quarterly Report |
Nov 05, 2024 | 4 | Filing |
Oct 24, 2024 | 8-K | Current Report |
Oct 15, 2024 | 4 | Filing |